Viewray reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -3.571%. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.008. According to our research, VRAY stock is a very good long-term investment. VRAY share price has been in a bull cycle for the past year. Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities.
Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts.
About ViewRay, Inc
According to analysts’ consensus price target of $6.75, ViewRay has a forecasted upside of 90.7% from its current price of $3.54. In the last two years, ViewRay’s EBITDA has decreased from $-108.20M to $-97.56M – a 9.83% drop. The next year looks promising for ViewRay, with analysts predicting EBITDA of $-101.70M – an increase of 4.24%. Over the next nine years, experts anticipate that ViewRay’s EBITDA will grow at a rate of 4.10%. In the last two years, ViewRay’s Free Cash Flow has fallen from $-87.33M to $-63.65M – a 27.12% decrease.
Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence . Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a https://day-trading.info/ trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year.
ViewRay MarketRank™ Forecast
ViewRay’s average quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRAY’s average quarter net income forecast represents a NaN% decrease compared to the company’s last quarter net income of $NaN . ViewRay’s average annual net income forecast for undefined is $NaN, with a range of $NaN to $NaN.
It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. ViewRay reports Q4 EPS , consensus Reports Q4 revenue $34.7M, consensus $33.89M. ViewRay had total cash and cash equivalents of $142.5M at December 31,… In 2025, VRAY is forecast to generate -$38,179,122 in earnings, with the lowest earnings forecast at -$38,179,122 and the highest earnings forecast at -$38,179,122. If ViewRay Inc takes out the full calculated possible swing range there will be an estimated 9.54% move between the lowest and the highest trading price during the day. This stock may move much during the day and with a large prediction interval from the Bollinger Band this stock is considered to be „high risk”.
Forecast EPS vs Actual EPS
According to undefined Wall Street analysts, ViewRay’s projected average quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRAY previous annual EPS of $NaN . Based on 8 analysts giving stock ratings to VRAY in the past 3 months. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
ViewRay’s EPS has decreased In the last two years, from $-1.12 to $-0.67 – a 40.18% drop. In the next year, analysts predict that EPS will reach $-0.83 – an increase of 23.78%. For the next nine years, the forecast is for EPS to grow by 25.08%.
The average price target for ViewRay is $6.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00. This represents a potential 76.55% upside from VRAY’s last price of $3.54. In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Viewray (VRAY – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $4.45.According to TipRanks, Thibault… The best way to use analyst ratings is to supplement your investment research.
ViewRay’s last stock rating was published by Piper Sandler on Aug 02, 2022. The company gave VRAY a „Overweight” rating, the same as its previous rate. The 8 analysts offering 1 year price forecasts for VRAY have a max estimate of — and a min estimate of —. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. High institutional ownership can be a signal of strong market trust in this company.
ViewRay EBITDA Forecast for 2023 – 2025 – 2030
ViewRay doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. As Warren Buffett has famously said, “If you’re not willing to own a stock for 10 years, don’t even think about owning it for 10 minutes.” The best way to realize gains in the… One share of VRAY stock can currently be purchased for approximately $3.54. A $226B Copper Spending JackpotOn November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time.
According to 14 analysts, the average rating for VRAY stock is „Buy.” The 12-month stock price forecast is $7.27, which is an increase of 105.95% from the latest price. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. This estimation is based on a high estimate of $10.00 and a low estimate of $7.00. Even if you are not interested in VRAY stock, you should still be aware of its competitors.
This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies. The company’s average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings. Zacks provides the average brokerage recommendation for thousands of stocks for most of the leading investment web sties.
During the last day, the stock moved $0.135 between high and low, or 3.87%. For the last week, the stock has had daily average volatility of 6.45%. There is no support from accumulated volume below today’s level and given the right condition the stock may global cloud team: our skills to grow your business success today perform very badly in the next couple of days. World’s first MRIdian center at Barnes-Jewish Hospital continues to lead the way for advanced precision cancer therapy with MRI-guided radiation DENVER , March 2, 2023 /PRNewswire/ — ViewRay, Inc. (N…
- The average price target for ViewRay is $6.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00.
- In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Viewray (VRAY – Research Report), with a price target of $7.00.
- VRAY stock returns are also predicted based on historical data.
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viewray (VRAY – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments.
- However, it can guide investors looking to buy or sell a stock.
The ViewRay Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.76 and $4.35. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, February 02, 2023, and so far it has fallen -25.63%.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Based on short-term price targets offered by seven analysts, the average price target for ViewRay comes to $7.14. The average price target represents an increase of 101.69% from the last closing price of $3.54. A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company’s earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate.
Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers. ViewRay issued an update on its FY 2023 earnings guidance on Monday, February, 27th. The company issued revenue guidance of $127.76 million-$143.09 million, compared to the consensus revenue estimate of $136.01 million. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. ViewRay has a short interest ratio („days to cover”) of 10.4, which indicates bearish sentiment. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock.